제약 자동화 시장 규모, 점유율, 예측, 동향 분석 : 제공 내용별, 자동화 방식별, 최종사용자별, 지역별 - 세계 예측(-2036년)

Pharmaceutical Automation Market by Offering (Solutions, Services), Mode of Automation (Semi-automatic, Fully Automatic), and End User (Large Pharmaceutical Manufacturers, CDMOs, Biotech) - Global Forecast to 2036

According to the latest research report titled, 'Pharmaceutical Automation Market by Offering (Solutions, Services), Mode of Automation (Semi-automatic, Fully Automatic), and End User (Large Pharmaceutical Manufacturers, CDMOs, Biotech) - Global Forecast to 2036,' the global pharmaceutical automation market is projected to reach approximately USD 39.57 billion by 2036 from an estimated USD 14.99 billion in 2026, at a CAGR of 10.2% during the forecast period (2026-2036). The robust growth of the pharmaceutical automation market is fundamentally driven by the accelerating transition towards Pharma 4.0, where the integration of advanced robotics, artificial intelligence, and the Industrial Internet of Things (IIoT) is redefining the efficiency, scalability, and compliance of pharmaceutical manufacturing.

As global demand for life-saving drugs, biologics, and personalized medicines continues to surge-exacerbated by aging populations and the rising prevalence of chronic diseases-pharmaceutical and biotech companies are increasingly turning to automated systems to achieve the high production throughput and stringent quality assurance required by regulatory bodies. Automated solutions, ranging from sophisticated plant-level controls like DCS and SCADA to advanced robotic arms and machine vision systems, are enabling manufacturers to minimize human error, reduce contamination risks, and ensure absolute data integrity throughout the production lifecycle. Furthermore, the expansion of continuous manufacturing and real-time release testing is necessitating a higher degree of process automation and digital synchronization. The convergence of digital twin technologies with real-world manufacturing environments is allowing companies to optimize development costs and switch times significantly, while sustainability-driven automation is helping reduce solvent consumption and energy waste. With significant investments in manufacturing infrastructure across emerging markets and the increasing adoption of collaborative robots (cobots) in lab and production settings, the pharmaceutical automation ecosystem is poised for a decade of transformative innovation, led by global technology giants and specialized automation providers.

Market Segmentation

The pharmaceutical automation market is segmented by offering (solutions and services), mode of automation (semi-automatic systems and fully automatic systems), end user (large pharmaceutical manufacturers, contract development & manufacturing organizations [CDMOs], and biotechnology & advanced therapy companies), and geography. The study also evaluates industry competitors and analyzes the market at the country level.

Based on Offering

By offering, the solutions segment holds the largest share of the overall pharmaceutical automation market in 2026. This dominance is attributed to the substantial demand for plant instrumentation, including robots, sensors, and machine vision systems, alongside plant-level controls such as Programmable Logic Controllers (PLC) and Distributed Control Systems (DCS) that form the backbone of automated manufacturing. However, the services segment is expected to witness significant growth during the forecast period, driven by the increasing complexity of integrating Pharma 4.0 technologies with legacy systems, necessitating professional advisory, installation, and ongoing maintenance and security services.

Based on Mode of Automation

By mode of automation, the fully automatic systems segment is expected to witness the fastest growth and hold a significant share of the market during the forecast period. The shift toward full automation is driven by the need for high-speed, high-volume production with minimal human intervention, particularly in sterile environments and for high-potency drug manufacturing. Fully automated lines provide superior consistency and traceability, which are critical for meeting the stringent quality standards of the pharmaceutical industry.

Based on End User

By end user, the large pharmaceutical manufacturers segment holds the largest share of the overall pharmaceutical automation market in 2026, as these organizations possess the capital and scale to implement comprehensive enterprise-level and plant-wide automation solutions. However, the Contract Development & Manufacturing Organizations (CDMOs) segment is projected to register the fastest growth during the forecast period. The rise of CDMOs is fueled by the pharmaceutical industry's increasing reliance on outsourcing to gain specialized manufacturing expertise and flexibility, leading CDMOs to invest heavily in advanced automation to offer competitive, high-quality, and scalable production services to their clients.

Geographic Analysis

An in-depth geographic analysis of the industry provides detailed qualitative and quantitative insights into the major regions (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa). In 2026, Europe holds the largest share of the overall pharmaceutical automation market, supported by the presence of numerous leading pharmaceutical companies and a strong heritage of industrial engineering and automation innovation. However, Asia-Pacific is expected to witness the fastest growth during the forecast period. This growth is driven by the massive expansion of pharmaceutical manufacturing in China and India, increasing government support for industrial automation, and the rising adoption of high-tech manufacturing solutions to meet both domestic healthcare needs and global export standards.

Key Players

The key players operating in the overall pharmaceutical automation market include Siemens AG (Germany), Emerson Electric Co. (U.S.), Mitsubishi Electric Corporation (Japan), ABB Ltd (Switzerland), FANUC CORPORATION (Japan), Honeywell International Inc. (U.S.), KUKA AG (Germany), Schneider Electric SE (France), Rockwell Automation, Inc. (U.S.), YASKAWA Electric Corporation (Japan), Yokogawa Electric Corporation (Japan), OMRON Corporation (Japan), Advantech Co., Ltd. (Taiwan), Fuji Electric Co., Ltd. (Japan), and Syntegon Technology GmbH (Germany).

Key Questions Answered in the Report-

• What is the current revenue generated by the pharmaceutical automation market?
• At what rate is the pharmaceutical automation market demand projected to grow for the next 7-10 years?
• What are the historical market sizes and growth rates of the pharmaceutical automation market?
• What are the major factors impacting the growth of this market? What are the major opportunities for existing players and new entrants in the market?
• Which segments in terms of offering, mode of automation, and end user are expected to create major traction for the vendors in this market?
• What are the key geographical trends in this market? Which regions/countries are expected to offer significant growth opportunities for the companies operating in the pharmaceutical automation market?
• Who are the major players in the pharmaceutical automation market? What are their specific product and service offerings in this market?
• What are the recent strategic developments in the pharmaceutical automation market? What are the impacts of these strategic developments on the market?

Scope of the Report:

Pharmaceutical Automation Market Assessment -- by Offering

• Solutions
  • Enterprise-level Controls (PLM, ERP, MES)
  • Plant Instrumentation (Robots, Sensors, Machine Vision Systems, Motors & Drives, Relays & Switches)
  • Plant-level Controls (SCADA, DCS, PLC)
• Services
  • Integration & Installation Services
  • Maintenance & Support Services
  • Advisory, Training, and Consulting Services
  • Safety & Security Services

Pharmaceutical Automation Market Assessment -- by Mode of Automation

• Semi-automatic Systems
• Fully Automatic Systems

Pharmaceutical Automation Market Assessment -- by End User

• Large Pharmaceutical Manufacturers
• Contract Development & Manufacturing Organizations (CDMOs)
• Biotechnology & Advanced Therapy Companies

Pharmaceutical Automation Market Assessment -- by Geography

• Europe
  • Germany
  • U.K.
  • Italy
  • Netherlands
  • Sweden
  • France
  • Spain
  • Rest of Europe
• Asia-Pacific
  • China
  • India
  • Japan
  • South Korea
  • Singapore
  • Rest of Asia-Pacific
• North America
  • U.S.
  • Canada
• Latin America
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa
  • South Africa
  • UAE
  • Saudi Arabia
  • Rest of Middle East & Africa

TABLE OF CONTENTS

1. Introduction

• 1.1. Market Definition
• 1.2. Market Ecosystem
• 1.3. Currency and Limitations
  • 1.3.1. Currency
  • 1.3.2. Limitations
• 1.4. Key Stakeholders

2. Research Methodology

• 2.1. Research Approach
• 2.2. Data Collection & Validation Process
  • 2.2.1. Secondary Research
  • 2.2.2. Primary Research & Validation
    • 2.2.2.1. Primary Interviews with Experts
    • 2.2.2.2. Approaches for Country-/Region-Level Analysis
• 2.3. Market Estimation
  • 2.3.1. Bottom-Up Approach
  • 2.3.2. Top-Down Approach
  • 2.3.3. Growth Forecast
• 2.4. Data Triangulation
• 2.5. Assumptions for the Study

3. Executive Summary

• 3.1. Overview
• 3.2. Market Analysis, by Offering
• 3.3. Market Analysis, by Mode of Automation
• 3.4. Market Analysis, by End User
• 3.5. Market Analysis, by Geography
• 3.6. Competitive Analysis

4. Market Insights

• 4.1. Overview
• 4.2. Market Drivers
  • 4.2.1. Rising Adoption of AI and Advanced Analytics in Pharmaceutical Manufacturing
  • 4.2.2. Expansion of Continuous Manufacturing and Real-Time Release Testing
  • 4.2.3. Increasing Demand for Biologics, Cell & Gene Therapy, and High-Precision Manufacturing
  • 4.2.4. Regulatory Emphasis on Data Integrity and Digital Compliance
• 4.3. Market Restraints
  • 4.3.1. High Capital Investment and Long Implementation Cycles
  • 4.3.2. Integration Challenges with Legacy Manufacturing Systems
• 4.4. Market Opportunities
  • 4.4.1. Adoption of IIoT, Cloud-Based Automation, and Edge Computing
  • 4.4.2. Sustainability-Driven Automation and Energy Optimization
  • 4.4.3. Expansion of Pharmaceutical Manufacturing in Emerging Markets
• 4.5. Market Challenges
  • 4.5.1. Cybersecurity Risks in Connected Manufacturing Ecosystems
  • 4.5.2. Shortage of Skilled Workforce for Advanced Automation Systems
  • 4.5.3. Interoperability and Standardization Issues
• 4.6. Market Trends
  • 4.6.1. Integration of Digital Twin and Simulation Technologies
  • 4.6.2. Growing Deployment of Robotics and Collaborative Robots (Cobots)
  • 4.6.3. Convergence of MES, SCADA, DCS, and Advanced Analytics Platforms
  • 4.6.4. Smart Inspection Systems and Vision-Based Quality Control
• 4.7. Porter's Five Forces Analysis
  • 4.7.1. Threat of New Entrants
  • 4.7.2. Bargaining Power of Suppliers
  • 4.7.3. Bargaining Power of Buyers
  • 4.7.4. Threat of Substitutes
  • 4.7.5. Competitive Rivalry
• 4.8. Value Chain Analysis
  • 4.8.1. Component and Hardware Suppliers
  • 4.8.2. Automation Hardware & Software Providers
  • 4.8.3. System Integrators
  • 4.8.4. Enterprise Automation & Analytics Providers
  • 4.8.5. Aftermarket Services and Lifecycle Support

5. Pharmaceutical Automation Market Assessment-by Offering

• 5.1. Overview
• 5.2. Solutions
  • 5.2.1. Enterprise-Level Controls
    • 5.2.1.1. Enterprise Resource Planning (ERP)
    • 5.2.1.2. Product Lifecycle Management (PLM)
    • 5.2.1.3. Manufacturing Execution Systems (MES)
  • 5.2.2. Plant Instrumentation
    • 5.2.2.1. Sensors
    • 5.2.2.2. Robots
      • 5.2.2.2.1. Articulated Robots
      • 5.2.2.2.2. Cartesian Robots
      • 5.2.2.2.3. Selective Compliance Assembly Robot Arms (SCARA)
      • 5.2.2.2.4. Collaborative Robots
      • 5.2.2.2.5. Other Robots
    • 5.2.2.3. Motors & Drives
    • 5.2.2.4. Machine Vision Systems
      • 5.2.2.4.1. Cameras
      • 5.2.2.4.2. Optics and LED Lighting
    • 5.2.2.5. Relays & Switches
    • 5.2.2.6. Other Plant Instrumentation Solutions
  • 5.2.3. Plant-Level Controls
    • 5.2.3.1. Programmable Logic Controllers (PLC)
    • 5.2.3.2. Distributed Control Systems (DCS)
    • 5.2.3.3. Supervisory Control and Data Acquisition (SCADA)
    • 5.2.3.4. Other Plant-Level Controls
• 5.3. Services
  • 5.3.1. Integration & Installation Services
  • 5.3.2. Maintenance & Support Services
  • 5.3.3. Advisory, Training, and Consulting Services
  • 5.3.4. Safety & Security Services

6. Pharmaceutical Automation Market Assessment-by Mode of Automation

• 6.1. Overview
• 6.2. Semi-Automatic Systems
• 6.3. Fully Automatic Systems

7. Pharmaceutical Automation Market Assessment-by End User

• 7.1. Overview
• 7.2. Large Pharmaceutical Manufacturers
  • 7.2.1. Small Molecule Manufacturers (OSD & Injectables)
  • 7.2.2. Biologics & Biosimilars Manufacturers
  • 7.2.3. Vaccine Manufacturers
  • 7.2.4. Others
• 7.3. Contract Development & Manufacturing Organizations (CDMOs)
• 7.4. Biotechnology & Advanced Therapy Companies
  • 7.4.1. Cell & Gene Therapy Developers
  • 7.4.2. mRNA & Novel Platform Developers
  • 7.4.3. Others

8. Pharmaceutical Automation Market Assessment-by Geography

• 8.1. Overview
• 8.2. Europe
  • 8.2.1. Germany
  • 8.2.2. U.K.
  • 8.2.3. Italy
  • 8.2.4. Netherlands
  • 8.2.5. Sweden
  • 8.2.6. France
  • 8.2.7. Spain
  • 8.2.8. Rest of Europe
• 8.3. Asia-Pacific
  • 8.3.1. China
  • 8.3.2. India
  • 8.3.3. Japan
  • 8.3.4. South Korea
  • 8.3.5. Singapore
  • 8.3.6. Rest of Asia-Pacific
• 8.4. North America
  • 8.4.1. U.S.
  • 8.4.2. Canada
• 8.5. Latin America
  • 8.5.1. Mexico
  • 8.5.2. Brazil
  • 8.5.3. Rest of Latin America
• 8.6. Middle East & Africa
  • 8.6.1. South Africa
  • 8.6.2. UAE
  • 8.6.3. Saudi Arabia
  • 8.6.4. Rest of the Middle East & Africa

9. Competition Analysis

• 9.1. Overview
• 9.2. Key Growth Strategies
• 9.3. Competitive Benchmarking
• 9.4. Competitive Dashboard
  • 9.4.1. Industry Leaders
  • 9.4.2. Market Differentiators
  • 9.4.3. Vanguards
  • 9.4.4. Emerging Companies
• 9.5. Market Share Analysis

10. Company Profiles

• 10.1. Siemens AG (Germany)
• 10.2. Emerson Electric Co. (U.S.)
• 10.3. Mitsubishi Electric Corporation (Japan)
• 10.4. ABB Ltd (Switzerland)
• 10.5. FANUC CORPORATION (Japan)
• 10.6. Honeywell International Inc. (U.S.)
• 10.7. KUKA AG (Germany)
• 10.8. Schneider Electric SE (France)
• 10.9. Rockwell Automation, Inc. (U.S.)
• 10.10. YASKAWA Electric Corporation (Japan)
• 10.11. Yokogawa Electric Corporation (Japan)
• 10.12. OMRON Corporation (Japan)
• 10.13. Advantech Co., Ltd. (Taiwan)
• 10.14. Fuji Electric Co., Ltd. (Japan)
• 10.15. Syntegon Technology GmbH (Germany)
• 10.16. Others

11. Appendix

• 11.1. Available Customization
• 11.2. Related Reports